<DOC>
	<DOCNO>NCT00086658</DOCNO>
	<brief_summary>Hypereosinophilic syndrome ( HES ) rare disease broad clinical sign symptom diagnose base persistent blood eosinophil count great 1500 cell , various end-organ damage ( include skin , heart , lung , nervous system digestive system etc . ) , exclusion know secondary cause hypereosinophilia . HES high morbidity/mortality rate . The major treatment HES systemic corticosteroid chemotherapeutic drug ( example , hydroxyurea interferon ) intention lower eosinophil count therefore slow progression disease . Even though corticosteroid therapy effectively reduce eosinophilia patient , may eventually become nonresponsive intolerable amount side effect long-term therapy medication . Mepolizumab humanize monoclonal antibody bind specifically human interleukin 5 ( hIL-5 ) inhibit activity . Previous human experience show effective reduce blood eosinophilia atopic HES patient alleviate HES clinical sign symptom . This study intend evaluate corticosteroid-sparing clinical benefit mepolizumab HES .</brief_summary>
	<brief_title>Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes ( HES )</brief_title>
	<detailed_description>A Multicenter , Randomized , Double-blind , Placebo-controlled , Parallel Group Phase III Study Evaluate Corticosteroid-reduction -sparing effect Mepolizumab 750 mg intravenously Subjects Hypereosinophilic Syndromes ( HES ) evaluate Efficacy Safety Mepolizumab control Clinical Signs Symptoms HES Nine Months</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<criteria>Inclusion criterion : Documented history Hypereosinophilic Syndrome ( HES ) Eosinophil count great 1500 cell 6 month Signs symptom organ system involvement No evidence parasitic , allergic cause eosinophilia comprehensive evaluation . Achieve maintain stable prednisone ( corticosteroid ) dose prior start study medication . Not pregnant nursing . Exclusion criterion : ChurgStrauss Syndrome Wegener 's Granulomatosis Lymphoma , hematological malignancy , advance metastatic solid tumor Chemotherapy , radiotherapy interleukin 2 treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hypereosinophilic Syndrome Hypereosinophilia</keyword>
	<keyword>mepolizumab</keyword>
	<keyword>anti IL-5</keyword>
</DOC>